Drug Profile
RSV-F protein subunit vaccine - GlaxoSmithKline
Alternative Names: RSV F subunit vaccine; RSV fusion glycoprotein subunit vaccine; RSV-F protein vaccineLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Novartis Vaccines
- Developer GSK
- Class Protein vaccines; Proteins; Respiratory syncytial virus vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers, In adults) in Belgium (IM)
- 27 Mar 2017 GlaxoSmithKline completes a phase I trial in Respiratory syncytial virus infection (In volunteers) in Belgium (NCT02298179)
- 01 Dec 2014 Phase-I clinical trials in Respiratory syncytial virus infections (In adults, In volunteers) in Belgium (IM) (NCT02298179)